NOVARTIS (CACZ885M2301)

By June 19, 2019 Closed

A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP

Leave a Reply